Antibiotics Market (By Drug Class: Cephalosporin, Penicillin, Fluoroquinolone, Macrolide, Carbapenem, Aminoglycoside, Sulfonamide, 7-ACA, Others; By Application: Skin infections, Urinary tract infection, Ear infection, Septicemia, Respiratory infections, Gastrointestinal infections; By Drug; By Action Mechanism; By Spectrum Of Activity; By Route of Administration; By Distribution Channel)- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

The global Antibiotics market size was estimated at USD 41.6 billion in 2021 and is expected to surpass around USD 59.21 billion by 2030 and poised to grow at a compound annual growth rate (CAGR) of 8.9% during the forecast period 2022 to 2030.

Key Takeaways:

  • North America antibiotics market was valued at USD 18.19 billion in 2021
  • By drug class, penicillin hit highest market share of over 26% in 2021
  • By action mechanism, cell wall synthesis inhibitors segment has garnered revenue share of 52% in 2021
  • Asia Pacific accounted highest market share of over 45.6% in 2021
  • North America and Europe region held the market share of around 47% in 2021

Global Antibiotics Market: Overview

The rising efforts by the pharmaceutical manufacturers and drug developers across the world on development of novel therapies aimed at treating various infectious diseases is one of the strongest motivators for the growth in the global antibiotics market in coming years. Furthermore, rising prevalence of various infectious diseases, such as pneumonia, tuberculosis, lower respiratory infections, and malaria is also driving the growth in the global antibiotics market. The resulting rise in the disease burden is motivating non-government as well as government authorities to fund research and development initiatives in order to fast track the development of novel antibiotic drugs and therapies.

The corporate survey report offers a comprehensive assessment of the contemporary trends that may impact the development of global antibiotics market over the forecast period i.e. 2022 to 2030. The report records the trajectory of global antibiotics market through base years and historic years to predict the performance of the sector till 2031. The business intelligence report takes a closer look at various segments in global antibiotics market and assesses these segments based on their status, size, share, revenue, and forecast to 2030. It also informs the readers about key driving as well as the restraining factors faced by the participants in the global antibiotics market.

Report Scope of the Antibiotics Market

Report Coverage


Market Size in 2022

USD 43.236 Billion

Market Size by 2030

USD 59.21 Billion

Growth Rate from 2022 to 2030

CAGR of 8.9%

Base Year


Forecast Period

2022 to 2030

Segments Covered

Drug Class, Application, Action Mechanism, Drug Origin, Spectrum Of Activity, Route of Administration, Distribution Channel, Geography

Companies Mentioned

Abbott Laboratories (US), Pfizer Inc. (US), Johnson & Johnson Services, GlaxoSmithKline PLC (UK), Sanofi (France), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (Switzerland), Bayer AG (Germany), Astellas Pharma Inc. (Japan)


Global Antibiotics Market: Major Trends and Drivers

The increase in the supportive government legislation pertaining to pharmaceutical production as well as the increasing prevalence of infectious diseases are two of the most significant drivers for the development of the global antibiotics market. Some other major driving factors propelling growth within the global antibiotics market include rise in the antibiotic resistance infections owing to the overuse or misuse of antibiotic drugs, resultant shift in prescription patterns to treat these bacterial infections through the usage of novel therapies, and rising global elderly population. Supportive legislative policies by governments across the world are also likely to aid in the expansion of the global antibiotics market in coming years.

Action Mechanism Insights

Cell wall synthesis inhibitors dominated the market in 2021 with a share of 52% and are anticipated to maintain their lead throughout the forecast period. High consumption as per prescription patterns and significant government funding are the key factors driving the segment. Cell wall synthesis inhibitors are the most widely used antibiotics as they are characterized by a wide spectrum of action against gram-positive and negative bacteria. Cell wall synthesis inhibitors are expected to witness significant growth over the forecast period owing to an increase in research activities, coupled with government funding. For instance, in February 2019, Bicycle Therapeutics announced the development of a novel cell wall synthesis inhibitor, after receiving a grant of USD 640,000 from the government of the U.K.

The RNA synthesis inhibitors segment is anticipated to witness significant growth over the forecast period due to the increase in the number of product launches and R&D efforts. For instance, in November 2020, Cosmo Pharmaceuticals N.V. introduced Aemcolo (rifamycin) as extended-release tablets for the treatment of Travelers’ Diarrhea in the U.S. Furthermore, the U.S. FDA granted Fast Track designations, Qualified Infectious Disease Product (QIDP) designation, and marketing exclusivity till 2028 for the product.

Drug Class Insights

Penicillin accounted for the largest share of 26% in 2021 and is expected to dominate the market over the forecast period due to maximum prescription and the largest number of generic manufacturers in the space. These drugs form the first line of choice in treating infections, such as pharyngitis, skin infections, bronchitis, gonorrhea, and ear infections. Cephalosporin emerged as the second-largest drug class segment after Penicillin and is expected to grow at a significant rate during the forecast period.

The cephalosporin and fluoroquinolone segments are expected to grow at a significant rate from 2022 to 2030. The growth of these segments can be attributed to the commercialization of new drugs during the forecast period. Currently, there are three cephalosporin drugs in the third phase of clinical trials and are anticipated to commercialize in the next 3 to 4 years. Moreover, the U.S. FDA approval of Shionogi’s Fetroja (cefiderocol) in November 2019 is expected to increase the market share. Similarly, the approval of Lasvic (lascufloxacin) by Japan PMDA and the new drug application submission by Wockhardt Ltd. in India is going to propel the growth of the fluoroquinolone segment.

The others segment is expected to grow at the fastest rate in the coming years owing to the presence of novel therapies in the pipeline, which are expected to launch over the forecast period. This segment consists of various existing classes of antibiotics as well as some newly developed antibiotic drugs, such as tetracyclines, lincosamides, imidazoles, amphenicols, oxazolidinone, and combination drugs. The commercialization of iclaprim, gepotidacin, ridinilazole, and zoliflodacin is anticipated to boost market growth during the forecast period.

Application Insights

On the basis of application, the market has been subdivided into skin infections, urinary tract infection, ear infection, septicemia, gastrointestinal infection and respiratory infections. Among these the respiratory infection has shown the maximum growth as a result of the huge number of patients who fall under this category. With the rapidly increasing global pollution and climate change the number of people suffering with respiratory disorders has increased tremendously. The outbreak of the pandemic had a severe impact on the respiratory system of the people which has proved to be a driving factor for the market.

Route of Administration Insights

On the basis of route of administration, the parenteral route it's the fastest growing market and has held the largest share whether it's high demand among the people. The rapidly increasing technological development and minimum amount of dose that is being administered with the help of syringes has boosted the demand tremendously. The rapidly rising number of patients who are getting admitted in hospitals in order to get treated for infections and ailments have helped this market to record a considerable growth during the forecast period.

The greater number of days which are patient has to spend in the premises of the hospital also proves to be a driving factor for the growth of the market. With the increasing time that the patient has to spend in the hospital premises the number of infections which the patient suffers with increases. 

Distribution Channel Insights

On the basis of distribution channel, the hospital sector has been considered as the largest as a result of the huge number of patients that choose a hospital set-up for getting treated in case of infections over the other types of health care sectors. The rapidly increasing specialized hospitals in the society has also attributed to the growth of this segment rapidly. The presence of specialists in the hospital domain has also proved to be a driving factor for the growth of the market.

With the increasing trend of online shopping people prefer to purchase medicines and drugs through the online pharmacies which has also proved to be a driving factor for the market. on the other hand, the retail pharmacies have shown a tremendous growth as a result of the increasing number of over-the-counter purchases performed by the patients in order to avoid the additional hospital expense.

Regional Insights

Asia Pacific held the largest share of 45.6% in 2021 and is expected to register a significant growth rate over the forecast period. This can be attributed to the high consumption of antibiotics, increase in the prevalence of infectious diseases, and rising government initiatives to develop novel therapies to treat drug-resistant infections. Moreover, the presence of generic players is contributing to the growth of the regional market. India and China are the biggest markets for antibiotics in the region. Unregulated sales and excessive consumption of antibiotics are the key factors supporting the market growth in these nations.

North America emerged as the second-largest regional market for antibiotics in 2021, followed by Europe. North America and Europe collectively held more than 47% share in 2021. These markets are highly regulated with well-developed healthcare infrastructure. The rising incidence of infectious diseases and growing healthcare expenditure by the government are among the key factors driving the North American market. The U.S. government is undertaking various measures, including antibiotic stewardship initiatives and promoting the R&D activities of innovative therapies to control infectious diseases.

Some of the prominent players in the Antibiotics Market include:

  • Abbott Laboratories (US)
  • Pfizer Inc. (US)
  • Johnson & Johnson Services
  • GlaxoSmithKline PLC (UK)
  • Sanofi (France)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Novartis AG (Switzerland)
  • Bayer AG (Germany)
  • Astellas Pharma Inc. (Japan)

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Antibiotics market

By Drug Class

  • Cephalosporin
  • Penicillin
  • Fluoroquinolone
  • Macrolide
  • Carbapenem
  • Aminoglycoside
  • Sulfonamide
  • 7-ACA
  • Others

By Application

  • Skin infections
  • Urinary tract infection
  • Ear infection
  • Septicemia
  • Respiratory infections
  • Gastrointestinal infections

By Action Mechanism

  • Cell Wall Synthesis Inhibitors
  • Protein Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • Mycolic Acid Inhibitors
  • Others

By Drug Origin

  • Natural
  • Synthetic

By Spectrum Of Activity

  • Broad-spectrum Antibiotic
  • Narrow-spectrum Antibiotic

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Retail pharmacies
  • Online pharmacies
  • Hospitals
  • Clinics

By Geography

North America

  • U.S.
  • Canada


  • Germany
  • France
  • United Kingdom
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Southeast Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Rest of Latin America

Middle East & Africa (MEA)

  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East & Africa

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Antibiotics industry analysis from 2022 to 2030 to identify the prevailing Antibiotics industry opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the global Antibiotics industry segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global Antibiotics industry trends, key players, market segments, application areas, and market growth strategies.

Report Detail

  • Report Code:6972
  • No. of Pages:150+
  • Format:PDF/PPT/Excel

Proceed To Buy

USD 3500
USD 7000